Exploratory experiment designed to discover new patterns targeting ACSL1, SCD1 in mouse serum, computational molecular docking. Primary outcome: direct binding confirmation between myricanol and ACSL1
This molecular interaction study employed cellular thermal shift assay (CETSA), molecular docking, and ELISA to confirm direct binding between myricanol and ACSL1 protein. The CETSA technique was used to demonstrate thermal stabilization of ACSL1 upon myricanol binding, while molecular docking provided computational validation of the binding interaction. ELISA measurements confirmed that myricanol treatment decreased concentrations of both ACSL1 and SCD1 in mouse serum. This experiment provided crucial mechanistic evidence that myricanol directly targets ACSL1 protein, establishing a molecular basis for its lipid-lowering effects through the ACSL1-SCD1 axis. The combination of biophysical, computational, and biochemical approaches provided robust evidence for direct protein-drug interaction.
Cellular thermal shift assay (CETSA) for protein thermal stabilization, molecular docking analysis for binding prediction, ELISA for serum protein concentration measurement
Thermal stabilization of ACSL1 by myricanol, favorable docking scores, decreased serum ACSL1 and SCD1 concentrations
Positive CETSA results indicating protein stabilization, computationally favorable binding interactions, significant reduction in serum protein levels
No related hypotheses
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.